Comparative Pharmacology
Head-to-head clinical analysis: CORTIFOAM versus FLOVENT DISKUS 250.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTIFOAM versus FLOVENT DISKUS 250.
CORTIFOAM vs FLOVENT DISKUS 250
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortifoam (hydrocortisone acetate) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell migration and cytokine release.
Fluticasone propionate is a corticosteroid with potent anti-inflammatory activity. It binds to the glucocorticoid receptor, leading to inhibition of pro-inflammatory cytokines, reduction of eosinophil recruitment, and suppression of airway hyperresponsiveness.
1 applicatorful (90 mg hydrocortisone acetate) rectally twice daily for 2-3 weeks, then every other day as needed.
250 mcg inhaled orally via DISKUS twice daily (500 mcg total daily dose).
None Documented
None Documented
Approximately 1.5-2 hours for hydrocortisone; clinically, effects persist longer due to local action.
Approximately 10-12 hours (terminal elimination half-life in asthmatics).
Primarily renal (about 70-90% as metabolites) and fecal (about 10-30% as metabolites).
Renal (approximately 5% as unchanged drug); fecal (majority as metabolites and unabsorbed drug).
Category C
Category C
Corticosteroid
Corticosteroid